Thierry Hercend
Chairman at GamaMabs Pharma SA
Profile
Thierry Hercend - Venture Partner
Thierry joined Andera Partners in 2006.
Thierry Hercend began his career in academia where he became a Professor of Immunology at the University of Paris and headed clinical biology laboratories and an INSERM research unit at the Gustave-Roussy Cancer Institute in Villejuif.
He has authored more than 120 papers in international peer reviewed journals.
He then joined the industry and acquired 15 years of senior R&D management experience in both the US and European pharmaceutical and biotechnology sectors, including VP Research Europe at Vertex Pharmaceuticals based in Oxford UK and VP global Oncology Research at Aventis based in Paris.
This combined experience has provided Thierry with an extensive network and know-how in research and development across various therapeutic areas.
He reviewed numerous biotechnology projects for partnership and/or acquisition when working in pharmaceutical companies and inversely was on the “sell” side when he was in the biotechnology industry.
He co-chaired on behalf of his companies the joint Research and Development committees of many collaborations between pharmaceutical and biotechnology companies.
These skills and knowledge are of particular relevance in the very stringent review process of opportunities and in providing technical and managerial advice to portfolio companies.
Thierry is currently Chairman of the board of Inotrem and GamaMabs and he is a member of the board of ImCheck, Poxel, Grey Wolf Therapeutics and Complix.
He was also a board member of U3 Pharma and PegaOne, and Chairman of the board of Oncoethix until their acquisition by large pharmaceutical companies.
Thierry is an M.D.
from the University of Paris and has a Ph.D.
in Immunology which he performed in Boston at Harvard Medical School (Boston) and the University of Paris.
Thierry Hercend active positions
| Companies | Position | Start |
|---|---|---|
Andera Partners SCA
 Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Private Equity Investor | 2005-12-31 |
GamaMabs Pharma SA
 GamaMabs Pharma SA Medical/Nursing ServicesHealth Services GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France. | Chairman | - |
Inotrem SA
 Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | Director/Board Member | - |
| U3 Pharma GmbH | Director/Board Member | - |
Grey Wolf Therapeutics Ltd.
 Grey Wolf Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Grey Wolf Therapeutics Ltd. is a biotechnology company, which engages in the drug discovery in immuno-oncology. It targets endoplasmic reticulum aminopeptidases 1 and 2 in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells. The company was founded by Thomas D. McCarthy and Peter Joyce and is headquartered in Oxford, the United Kingdom. | Director/Board Member | - |
Former positions of Thierry Hercend
| Companies | Position | End |
|---|---|---|
Aventis SA
 Aventis SA Pharmaceuticals: MajorHealth Technology Aventis SA develops pharmaceuticals and vaccines for preventative medicine. The company is located in Schiltigheim, France. | Corporate Officer/Principal | - |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 2001-12-31 |
Institut Gustave Roussy EURL
 Institut Gustave Roussy EURL Miscellaneous Commercial ServicesCommercial Services Institut Gustave Roussy EURL is a cancer research and treatment center that places innovation at the heart of its services. The private company is based in Chevilly-Larue, France, and has subsidiaries in France. The center has strong partnerships at national and international levels to provide high-value care to all its patients. Patients' rights are protected and guaranteed to ensure their autonomy, respect for their individual liberties, and dignity within the hospital. | Corporate Officer/Principal | - |
| Université de Paris XI Paris Sud | Corporate Officer/Principal | - |
| ░░░░░░░░ ░░░░░░░░░░░░░░░ ░░ | ░░░░░░░░ | - |
Training of Thierry Hercend
| Université Paris 1 Panthéon-Sorbonne | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| POXEL | Health Technology |
| Private companies | 14 |
|---|---|
Genticel SA
 Genticel SA BiotechnologyHealth Technology Genticel SA operates as a clinical stage biotechnology company, which focuses on the development of immunotherapies designed to fight infectious diseases and cancer. The company was founded by Bénédikt Timmerman and Ludovic de Meeus d'Argenteuil on October 15, 2001 and is headquartered in Labège, France. | Health Technology |
Complix NV
 Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Health Technology |
Laboratoire Français du Fractionnement et des Biotechnologies
 Laboratoire Français du Fractionnement et des Biotechnologies BiotechnologyHealth Technology Laboratoire Francais du Fractionnement et des Biotechnologies SA provides plasma-derived medicinal products. It undertakes research and development programs in plasma fractions and biotechnologies in the areas of autoimmune diseases and hemostasis disorders. The firm's products include albumin and immunoglobulin. It also offers products for rare pathologies. The company was founded in 1994 and is headquartered in Les Ulis, France. | Health Technology |
| Roussel Uclaf SA | Health Technology |
Andera Partners SCA
Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Finance |
Aventis SA
Aventis SA Pharmaceuticals: MajorHealth Technology Aventis SA develops pharmaceuticals and vaccines for preventative medicine. The company is located in Schiltigheim, France. | Health Technology |
GamaMabs Pharma SA
GamaMabs Pharma SA Medical/Nursing ServicesHealth Services GamaMabs Pharma SA specializes in developing monoclonal antibodies. It offers research and development solutions for biopharmaceutical industry. The company was founded by Jean-Francois Prost and Stephane Degove in June 2013 and is headquartered in Toulouse, France. | Health Services |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | Health Technology |
OncoEthix SA
 OncoEthix SA Pharmaceuticals: MajorHealth Technology OncoEthix SA operates as a clinical stage biotechnology company which develops cancer drugs. Its products include OTX008, OTX015, and OTX009. The company was founded by Esteban Cvitkovic, Jeanne Kay Noel, Yves Paternot, and Patrice Herait in March 2007 and is headquartered in Luzern, Switzerland. | Health Technology |
Cytomics Pharmaceuticals SA
 Cytomics Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Cytomics Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing drugs that control the degradation of proteins, to treat major human diseases. The company was founded in April 2000 in collaboration with Dominique Thomas (Research Director at the Center for Molecular Genetics of the CNRS) and Richard Benarous (Director of the Department for Infectious Diseases 'at the Cochin Institute of Molecular Genetics), both specialists recognized by the ubiquitin-proteasome protein degradation. | Health Technology |
| U3 Pharma GmbH | |
| Université de Paris XI Paris Sud | Consumer Services |
Institut Gustave Roussy EURL
Institut Gustave Roussy EURL Miscellaneous Commercial ServicesCommercial Services Institut Gustave Roussy EURL is a cancer research and treatment center that places innovation at the heart of its services. The private company is based in Chevilly-Larue, France, and has subsidiaries in France. The center has strong partnerships at national and international levels to provide high-value care to all its patients. Patients' rights are protected and guaranteed to ensure their autonomy, respect for their individual liberties, and dignity within the hospital. | Commercial Services |
Grey Wolf Therapeutics Ltd.
Grey Wolf Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Grey Wolf Therapeutics Ltd. is a biotechnology company, which engages in the drug discovery in immuno-oncology. It targets endoplasmic reticulum aminopeptidases 1 and 2 in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells. The company was founded by Thomas D. McCarthy and Peter Joyce and is headquartered in Oxford, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Thierry Hercend
